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Introduction 
CDC has developed this policy on unused smallpox vaccine in response to questions raised by several 
smallpox vaccination programs and to provide a recommendation on maintaining a readiness to respond 
to an attack involving the use of smallpox. The sections below describe why CDC recommends that all 
smallpox vaccination programs should continue to maintain unopened vials of Dryvax ® vaccine to assure 
a readiness to respond to a smallpox outbreak or to continue vaccination activities. 
Background 
The goal of smallpox preparedness is to ensure federal, state, and local health agencies have the optimal 
capacity to respond to a smallpox outbreak. National smallpox preparedness capacity has been increased 
by: (1) offering vaccination safely to volunteer public health teams (including vaccinators) in order to 
conduct investigations and outbreak control for the initial cases of a smallpox event; and (2) offering 
vaccinations safely to key volunteer healthcare workers who would treat and manage the initial smallpox 
cases and suspects.  
The currently available licensed smallpox vaccine Dryvax ® was produced more than 20 years ago and 
has been remarkably stable since that time. Its storage and handling requirements are similar to those of 
other licensed vaccines, and are detailed in the website listed below in the Unopened Vials of Smallpox 
Vaccine section. To assure a readiness to respond to a smallpox outbreak, the post-event smallpox 
vaccine inventory and ancillary supplies will be maintained by the Strategic National Stockpile (SNS) in 
addition to the more modest supplies of smallpox vaccine deployed for pre-event vaccination efforts 
conducted by state and local health agencies.  
Following the attacks of September 11, 2001, fears about potential terrorist attacks involving smallpox 
prompted the removal of some Dryvax ® smallpox vaccine supplies from storage facilities maintained at -
20 o C to cold stores maintained at 2 o to 8 o C in order to conduct testing for re-licensure of the product.  
It is the intent of Wyeth Pharmaceuticals, manufacturer of Dryvax ® (smallpox vaccine), to continue to 
monitor and perform routine tests, as required, on the vaccine that has been released under their license. 
These tests include potency of distributed lots of Dryvax ® and, if appropriate, provide a notice of dating 
extension for all lots of vaccine. Notification of dating extension will occur via the State and Local 
Preparedness Program in the Office of Terrorism Preparedness and Emergency Response (SLPP), SNS, and 
the National Immunization Program (NIP). Considering the stability of Dryvax ®, CDC believes that this 
potency testing process is likely to result in dating extensions for the foreseeable future or until the new 
smallpox vaccine is licensed and available.  
Unopened Vials of Smallpox Vaccine 
CDC recommends that unopened vials of Dryvax ® vaccine distributed for pre-event vaccination efforts 
continue to be maintained by state and local health agencies to assure a readiness to respond to a 
smallpox outbreak or to continue vaccination activities. In contrast to pediatric vaccines that are routinely 
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returned for credit or disposal, once Dryvax ® is distributed, it will not be recovered by CDC for 
redistribution and/or disposal.  
As part of their post event smallpox plan, state and urban area BT programs have the flexibility to forward 
deploy local stores of Dryvax ®, e.g., in local clinics or hospitals. Forward deployment must follow the 
policies and procedures described in the “Guidelines for Smallpox Vaccine Packing and Shipping” 
developed by SNS in January 2003 (available from 
http://www.bt.cdc.gov/agent/smallpox/vaccination/pdf/packing-shipping.pdf). 
Opened Smallpox Vaccine Vials 
CDC recommends that unopened vials of Dryvax® vaccine distributed for pre-event vaccination efforts 
continue to be maintained by state and local health agencies to assure a readiness to respond to a 
smallpox outbreak or to continue vaccination activities. In contrast to pediatric vaccines that are routinely 
returned for credit or disposal, once Dryvax® is distributed, it will not be recovered by CDC for 
redistribution and/or disposal.  
As part of their post event smallpox plan, state and urban area BT programs have the flexibility to forward 
deploy local stores of Dryvax®, e.g., in local clinics or hospitals. Forward deployment must follow the 
policies and procedures described in the “Guidelines for Smallpox Vaccine Packing and Shipping” 
developed by the Strategic National Stockpile (SNS) in January 2003 (available from 
http://www.bt.cdc.gov/agent/smallpox/vaccination/pdf/packing-shipping.pdf). This document also 
describes policies and procedures regarding smallpox vaccine storage and handling (Section 2) and 
protecting smallpox vaccines and diluent (pages 3-5). 
Two major problems in storage and handling can rapidly reduce vaccine potency: 1) freezing vaccines that 
should not be frozen or 2) letting infectious (live) vaccines warm. Smallpox vaccine must be kept at 
appropriate temperatures to retain effectiveness.  
• Smallpox vaccine should be kept between 2°to 8°C (36° to 46°F).  
• Smallpox vaccine, like DTaP, Hep A, Hep B, Hib, PCV and IPV, should never be frozen.  
• Diluents should not be frozen.  
• Smallpox vaccine should always be protected from heat.  
Dryvax® vaccine that has been frozen should be discarded using vaccine disposal procedures noted in the 
following section.  
Dryvax® vaccine that has been exposed to temperatures above 8°C (46°F) should be quarantined at 2°to 
8°C (36° to 46°F) and not used for vaccination unless approval is provided by Drug Services, Scientific 
Resources Program, National Center for Infectious Diseases at CDC. Smallpox vaccination programs must 
contact Drug Services by calling (404) 639-3670 to receive approval for use of Dryvax® vaccine subjected 
to temperatures above 8°C (46°F). 
Questions regarding the use of Dryvax® vaccine diluent in smallpox vaccine kits exposed to temperatures 
outside the recommended range of 2° to 8°C (36° to 46°F) should also be directed to CDC Drug Services. 
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Smallpox Vaccine Disposal 
Unopened vials of smallpox vaccine which have been frozen, subjected to temperatures of <2°C, or >8°C 
and not approved for use by CDC Drug Services, or have passed expiration and/or extension dating, 
should be discarded using medical waste disposal procedures. Vaccine vials can be dropped into the 
hospital sharps container and autoclaved, or disposed of following the procedure for all other biohazard 
materials. These instructions are also true for empty, used smallpox vaccine vials and unused, unopened 
vials which have exceeded the expiration date. 
In places where medical waste is buried, soaking the medical waste in a 1:10 dilution of bleach for at least 





































For more information, visit www.cdc.gov/smallpox, 
or call CDC at 800-CDC-INFO (English and Spanish) or 888-232-6348 (TTY). 
